|
|
|
| Clinical Efficacy and Mechanism of Different Neoadjuvant Chemotherapy Administrations in the Treatment of Advanced Cervical Cancer |
| GAO Zi-xuan, SHANG Xue, ZHENG Min-hui |
| Department of Gynecology, Zhongshan Boai Hospital, Zhongshan Guangdong, 528400 |
|
|
|
|
Abstract 【Objective】To investigate the expression of PI3K/AKT/mTOR signaling pathway and clinical efficacy of different Neoadjuvant Chemotherapy administration (Paclitaxel+Cisplatin) for advanced cervical cancer. 【Methods】From March 2016 to March 2018, 68 patients with advanced cervical cancer who received neoadjuvant chemotherapy in Boai Hospital of Zhongshan City were selected. According to the random table method, they were divided into the interventional group (neoadjuvant interventional arterial chemotherapy) and the intravenous group (neoadjuvant intravenous chemotherapy), with 34 cases in each group. The levels of p-PI3K, p-Akt, p-mTOR, matrix metalloprotease 2 (MMP2) and vascular endothelial growth factor (VEGF) were compared between the two groups. The short-term efficacy and adverse reactions were recorded and compared as well. 【Results】The effective rate of the intervention group was higher than that of the intravenous group, and the incidence of adverse reactions was lower than that of the intravenous group (P<0.05). The levels of p-PI3K, p-Akt, p-mTOR, MMP2 and VEGF protein in cervical cancer tissues of intervention group were significantly lower than those of venous group (P<0.05). 【Conclusion】The short-term efficacy of neoadjuvant interventional arterial chemotherapy for advanced cervical cancer treatment is better than neoadjuvant intravenous chemotherapy. It can effectively inhibit the PI3K/AKT/mTOR signaling pathway in cervical cancer cells, which may be related to the significant inhibition of its phosphorylation.
|
|
Received: 07 December 2018
|
|
|
|
|
|
[1] Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2] Chen Z,Shi Y,Wang S,et al.Meta-analysis showing that early response to neoadjuvant chemotherapy predicts better survival among cervical cancer patients[J].Oncotarget,2017,8(35):59609-59617.
[3] Ma J,Song J,Chen H,et al.Intra-arterial interventional therapy for inoperable local advanced breast cancer: A retrospective study[J].Oncol Lett,2018,15(2):1955-1962.
[4] 麻宏亮,张洪涛.化疗联合中药对中晚期非小细胞肺癌患者免疫功能和KPS 评分的影响[J].海南医学,2014,25(15):2271-2272.
[5] 张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.
[6] 世界卫生组织.抗癌药急性及亚急性毒性反应分度标准[J].癌症,1992,11(3):207-210.
[7] 刘慧强.我国宫颈癌流行病学特征和高危因素分析[J].中国妇幼保健,2016 ,31(6):1258-1260.
[8] 赵辉,吴玉梅.新辅助化疗在治疗局部晚期宫颈癌中的应用进展[J].重庆医学,2018,47(4):558-560.
[9] 王昕雯,高迎春.奈达铂或顺铂分别联合紫杉醇同步放疗用于中晚期宫颈癌的疗效比较[J].中国药房,2017,28(3):318-320.
[10] 刘海霞.紫杉醇联合卡铂化疗同步放疗治疗中晚期宫颈癌近期疗效观察[J].山东医药,2017,57(6):83-84.
[11] 杜鲁豫,陈怀博.新辅助化疗方案联合手术治疗晚期宫颈癌的效果及安全性探讨[J].癌症进展,2016,14(3):245-247,250.
[12] 张志芳,王志莲.PI3K/AKT/mTOR 信号通路在妇科恶性肿瘤中的研究进展[J].世界最新医学信息文摘,2018,18(18):85-92.
[13] 白煜.新辅助化疗不同给药途径对宫颈癌组织中癌细胞生长信号通路功能的影响[J].海南医学院学报,2018,24(02):216-219. |
|
|
|
2019, Vol. 36 
